SCHEMBL14901538

SCHEMBL14901538

CC(=O)OCCOc1ccc(Sc2ccc(OCCCCl)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 2/20 0.42
LMNA P02545 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
MAPT P10636 3/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
P2RY12 Q9H244 1/20 0.39
THRB P10828 2/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MITF O75030 1/20 0.38
XBP1 P17861 1/20 0.38
NOD2 Q9HC29 1/20 0.38
ALDH1A1 P00352 3/20 0.38
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37
APP P05067 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12517385 0.90 FFAR1 (0.45) L3MBTL1LMNAALDH1A1
SCHEMBL14901539 0.86 L3MBTL1 (0.47) L3MBTL1GAAMAPTPDE3BPDE3A
SCHEMBL14901537 0.86 L3MBTL1 (0.47) L3MBTL1GAAHPGDMAPTPDE3B
SCHEMBL14901534 0.83 L3MBTL1 (0.53) L3MBTL1GAALMNAMAPTALDH1A1
SCHEMBL10030181 0.82 L3MBTL1 (0.55) L3MBTL1GAALMNASMN1; SMN2MAPT
SCHEMBL14901533 0.82 KCNA3 (0.41) L3MBTL1GAALMNASMN1; SMN2HPGD
SCHEMBL27495385 0.81 ALDH1A1 (0.47) L3MBTL1GAALMNASMN1; SMN2MAPT
SCHEMBL12516025 0.81 AR (0.54) L3MBTL1GAALMNASMN1; SMN2MAPT
SCHEMBL25118385 0.79 THRB (0.57) L3MBTL1GAALMNASMN1; SMN2HPGD
SCHEMBL6936853 0.78 MAPT (0.66) L3MBTL1GAALMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE SHBG, KLK3, HSD17B11 L3MBTL1 2335/4885GAA 2231/4885LMNA 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.